Amiodarone is an iodine-rich drug used to treat cardiac dysrhythmias. The structure of amiodarone resembles that of thyroxine, and treatment with amiodarone may alter thyroid function. The effects of antenatal amiodarone use on fetal/neonatal thyroid function have only been addressed in a limited number of patient reports. We describe two cases of transient neonatal hypothyroidism due to in utero amiodarone exposure, followed by a brief review of the available literature.
INTRODUCTION
Amiodarone, a benzofuran derivative, is a very effective antiarrhythmia drug. 1 Amiodarone contains 37% iodine by weight, and its structure resembles that of thyroxine (T4). 2 Not surprisingly, amiodarone therapy may affect thyroid function via numerous mechanisms at the pituitary, thyroid, and peripheral levels. 2 Although most patients treated with amiodarone remain euthyroid, clinically relevant thyroid dysfunction (either hypothyroidism or hyperthyroidism) occurs in 14 to 18% of chronically treated patients. 2 Amiodarone has been used during pregnancy for treatment of both maternal and fetal dysrhythmias. Substantial transplacental passage of both amiodarone and its metabolite desethylamiodarone occurs. 3 The effects of amiodarone during pregnancy on neonatal thyroid function have only been addressed in a limited number of reports. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] We describe two patients with transient neonatal hypothyroidism due to in utero amiodarone exposure.
CASE REPORTS
In the first infant, born at 35 weeks gestation, fetal tachycardia had been diagnosed at 29 weeks. This persisted despite treatment with digoxin and flecainide. An ultrasound at 31 weeks gestation revealed hydrops fetalis, so the mother was begun on amiodarone 400 mg daily with subsequent control of tachycardia and resolution of hydrops (total of 4 weeks of treatment). Physical examination at birth was normal. There was no goiter. The heart rate was regular, without tachycardia. Thyroid stimulating hormone (TSH) was 134 mIU/ml and total thyroxine (T4) 3.4 mg/dl on day of life 3. The infant was started on levothyroxine 10 mg/day IV (NPO for possible necrotizing enterocolitis). He was eventually switched to oral levothyroxine 25 mg/day on day of life 17, when feeding resumed. Thyroid function tests rapidly normalized. He was last seen at 4 months of age, and his development, growth parameters, physical examination, and thyroid function tests were all normal. He has subsequently been lost to follow-up.
The second infant was born at 36 weeks gestation by spontaneous vaginal delivery. The pregnancy was complicated by fetal supraventricular tachycardia, first diagnosed at 31 weeks gestation. The mother was treated with digoxin for the last 5 weeks of pregnancy, and amiodarone was added for the last 19 days (800 mg twice daily for 4 days and then 600 mg twice daily for 15 days) for persistent fetal tachycardia. The infant did well in the perinatal period, but he was admitted on day of life 6 for tachycardia and an apneic spell at home. He was placed on digoxin with normalization of the heart rate. On day of life 8, TSH was 252 mIU/ml and total T4 2.7 mg/dl. There was no thyromegaly. A technetium scan revealed intense uptake of tracer in a bilobed thyroid gland in the usual position in the neck, making a diagnosis of amiodarone-induced hypothyroidism most likely. The infant was started on levothyroxine 25 mg daily, and thyroid function tests normalized rapidly. Levothyroxine was discontinued at 5 months of age, and thyroid function tests have remained normal off therapy. At 21 months of age, his development is delayed. While he is able to feed himself with a fork or spoon, he just began walking independently. He babbles occasionally but says no definite words and cannot follow simple commands. A brain MRI and hearing test were normal.
DISCUSSION
The mechanism of amiodarone-induced hypothyroidism is most likely related to the Wolff-Chaikoff effect, 2 the process of decreased oxidation and coupling of iodine to thyroglobulin (organification) with increasing doses of iodine. This is partly relieved with repeated large doses of iodine (''escape from the Wolff-Chaikoff effect'').
With amiodarone therapy during pregnancy, the fetus is exposed to excess iodine, because like with iodine, transplacental transfer of amiodarone and desethylamiodarone occur. Since the fetal thyroid gland escapes from the Wolff-Chaikoff effect only during late gestation, the iodine overload may be responsible for a persistent inhibition of fetal thyroid function, which may lead to hypothyroidism and goiter. 3 There are 69 reported cases of amiodarone use during pregnancy in which the infants' thyroid function was documented. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] In all, 16 infants developed hypothyroidism 3, [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] ( Table 1) , and two developed hyperthyroidism. 18, 19 The overall incidence of hypothyroidism was 23% (16/69). Amiodarone was used for treatment of both maternal and fetal dysrhythmias. In infants who developed hypothyroidism, maternal amiodarone doses ranged from 200 to 1600 mg/day. Amiodarone was given directly to the fetus via the umbilical vein in only three cases. 9, 16 Duration of amiodarone treatment ranged from 2 days to 40 weeks. Neither cumulative amiodarone dose nor duration of amiodarone exposure was related to development of hypothyroidism in the fetus. 56% (9/16) of the hypothyroid infants were exposed to amiodarone during the third trimester only, whereas 19% (3/16) were exposed for >25 weeks (data on the other four are not known). Conversely, 50% of the euthyroid infants were exposed to amiodarone for the duration of pregnancy, and 41% were exposed during the third trimester only. 3 Our two infants required less than 1 month of amiodarone exposure to develop hypothyroidism. Only 13% (2/16) of the infants developed a detectable goiter, 10, 11 and this was not related to cumulative dose of amiodarone or duration of exposure. In all cases, the thyroid abnormality was transient. Short-term thyroid replacement was documented in only 44% (7/16) of the infants. [9] [10] [11] [12] 16, 18 Limited data are available on the long-term neuropsychological development of infants exposed to amiodarone during pregnancy, with only anecdotal data for those with amiodarone-induced hypothyroidism [9] [10] [11] [12] 17, 18 ( Table 1 ). The largest report 20 retrospectively evaluated 10 children exposed to amiodarone in utero for 8 to 40 weeks compared to age-matched controls. There were eight toddlers (mean age 18 months) and two older children aged 9 and 12 years. Two of the toddlers had transient thyroid abnormalities (one with hypothyroidism and one with hyperthyroidism). The eight toddlers as a group had normal scores on Bayley and Reynell neurodevelopment testing compared with controls. The two toddlers with transient thyroid abnormalities had similar test scores as the rest of the group. One toddler who was euthyroid had delayed Denver developmental milestones and had the lowest Bayley and Reynell scores, and at 3-year follow-up, he had moderate delays in speech, language, and motor skills. The two older children had normal IQ scores but had variable deficiencies in other areas of testing. Thus, fetal amiodarone exposure may lead to neurodevelopmental abnormalities in some children. This may be due to a direct neurotoxic effect of amiodarone on the fetal brain. However, the contribution of maternal cardiac disease, other maternal medications, and fetal thyroid insufficiency cannot be ruled out.
CONCLUSION
The use of amiodarone during pregnancy for maternal or fetal dysrhythmias may lead to transient neonatal hypothyroidism, usually not associated with goiter. It is unrelated to either the dose or duration of amiodarone treatment. Exposure to amiodarone may also be associated with neurodevelopmental abnormalities, even in the absence of thyroid disease, but completely normal development has also been reported. Obstetricians, pediatricians, and neonatologists should be aware of the potential for amiodarone to affect the thyroid axis, even after relatively short treatment duration, so that evaluation for and treatment of neonatal hypothyroidism can begin in a timely manner.
